<DOC>
	<DOCNO>NCT02085460</DOCNO>
	<brief_summary>To investigate efficacy safety rebamipide liquid chemoradiotherapy-induced oral mucositis patient head neck cancer follow administration rebamipide determine optimal dose rebamipide .</brief_summary>
	<brief_title>A Phase 2 Trial Rebamipide Liquid Determine Effective Dose Prevention Chemoradiotherapy-induced Oral Mucositis Patients With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>Head neck cancer patient schedule definitive postoperative chemoradiotherapy . Patients histopathological diagnosis head neck cancer primary tumor one follow region . 1 . Definitive therapy : nasopharynx , oropharynx , hypopharynx , larynx 2 . Postoperative therapy : oral cavity , ropharynx , hypopharynx , larynx Patients history chemotherapy , radiotherapy , chemoradiotherapy head neck cancer Patients Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Patients able hold fluid mouth Patients able swallow investigational medicinal product ( IMP ) Patients expect survive least 3 month Patients give write informed consent person Patients stay visit hospital schedule examination observation Patients able take contraceptive measure avoid pregnancy patient partner time inform consent 4 week completion IMP administration Patients primary malignant tumor head neck cancer . Patients symptomatic viral , bacterial , fungal infection Patients serious renal impairment Patients distant metastasis Patients severe complication ( uncontrolled cardiac disease , diabetes , hypertension , etc ) Patients follow laboratory test result : 1 . Neutrophil count : &lt; 1500 L 2 . Platelet count : &lt; 75000 L 3 . Hemoglobin : &lt; 10.0 g/L 4 . Aspartate aminotransferase ( AST ) : &gt; 3 time upper limit reference value trial site 5 . Alanine aminotransferase ( ALT ) : &gt; 3 time upper limit reference value trial site 6 . Serum bilirubin : &gt; 1.5 time upper limit reference value trial site 7 . Serum albumin : &lt; 3.0 g/dL 8 . Serum creatinine : &gt; 1.5 upper limit reference value trial site 9 . Creatinine clearance : &lt; 30 mL/min Patients complicate autoimmune disease Patients require continuous systemic administration glucocorticoid Female patient pregnant lactating , may possibly pregnant , wish become pregnant Patients participate clinical trial within 4 week prior initiation chemoradiotherapy Patients history drug allergy rebamipide , cisplatin , platinum compound Patients otherwise judged investigator subinvestigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>